98%
921
2 minutes
20
Cardiovascular disease is the predominant cause of mortality and severe disability. Cardiomyocytes (CMs) derived from human embryonic stem cells (hESCs) have good application prospects for treating this disease. Unfortunately, CMs generated via current methods are relatively immature, as proven by defects such as sarcomer-like structures, calcium processing capacity and mitochondrial maturity. Therefore, in this study, tunable PDMS substrates that modified with sufficiently thick synthetic coatings were prepared to regulate both the myocardial differentiation of hESCs and subsequent maturation. Surprisingly, the effect of substrate elasticity on the critical attachment of hESCs and hESC-CMs vanished when common Matrigel coatings were used, but apparent differences were detected in the synthetic group. Rigid substrates promoted the adhesion of hESCs but not hESC-CMs. Moreover, the PDMS substrates with the highest hardness remarkably promoted the myocardial differentiation of hESCs, which was even better than that of the rigid plate group. The softest PDMS achieved the best performance among the groups in terms of the maturation of hESC-CMs, as confirmed by enhanced functional, metabolic, and ultrastructural maturation. This study reveals the real impact of an elastic substrate on the adhesion, differentiation, and maturation of hESC-CMs, which has value for accelerating the development of clinically applicable mature hESC-CMs with high induction efficiency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.colsurfb.2025.114540 | DOI Listing |
Mol Biol Rep
September 2025
Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, 91766-1854, USA.
Regenerative cardiology has emerged as a novel strategy to improve cardiac healing following ischemic injury. While stem-cell-mediated cardiac regeneration has garnered much attention as a promising strategy, its value remains debated owing to the lack of ideal stem cell source candidates. Resident/endogenous cardiac-derived stromal cells (CSCs) exhibit superior therapeutic potential due to their innate abilities to differentiate into cardiac cells, especially cardiomyocytes (CM).
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Department of Neurosciences, Institute of Human Anatomy, University of Padova, 35121 Padova, Italy.
Harlequin syndrome, also known as differential hypoxia (DH) or North-South syndrome, is a serious complication of femoro-femoral venoarterial extracorporeal membrane oxygenation (V-A ECMO). Moreover, Harlequin syndrome is caused by competing flows between the retrograde oxygenated ECMO output and the anterograde ejection of poorly oxygenated blood from the native heart. In the setting of impaired pulmonary gas exchange, the addition of an Impella device (ECPELLA configuration), although beneficial for ventricular unloading and hemodynamic support, may further exacerbate this competition and precipitate DH.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, 453003 Xinxiang, Henan, China.
Myocarditis is a life-threatening inflammatory disorder that affects the cardiac muscle tissue. Current treatments merely regulate heart function but fail to tackle the root cause of inflammation. In myocarditis, the initial wave of inflammation is characterized by the presence of neutrophils.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Department of Emergency, The First People's Hospital of Guiyang, Guiyang, China.
Objective: Sepsis is a common and life-threatening syndrome in intensive care units, frequently accompanied by myocardial dysfunction, which significantly worsens patient outcomes. S100A12, a calcium-binding protein associated with inflammation, is upregulated in various inflammatory conditions. However, its role in sepsis and related cardiac injury remains unclear.
View Article and Find Full Text PDFRes Pract Thromb Haemost
August 2025
Department of Cardiology, State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China.
Background: The selection of P2Y12 inhibitors for acute coronary syndrome patients after percutaneous coronary intervention (PCI) remains controversial among East Asian patients.
Objectives: This study aimed to identify the optimal P2Y12 inhibitor selection for the East Asian population carrying loss-of-function (LOF) alleles based on the Global Registry of Acute Coronary Events (GRACE) score.
Methods: Between March 2016 and March 2019, a cohort of 8683 patients diagnosed with acute coronary syndrome who survived PCI were enrolled in this study.